KalVista Pharmaceuticals, Inc KALV will launch profits outcomes for the very first quarter before the opening bell on Thursday, Sept. 11.
Experts anticipate the Cambridge, Massachusetts-based business to report a quarterly loss at 96 cents per share, versus a year-ago loss of 87 cents per share. KalVista Pharmaceuticals tasks to report quarterly profits of $2.09 million, according to information from Benzinga Pro.
On Aug. 11, KalVista Pharmaceuticals revealed upkeep of Orphan Classification for Sebetralstat in the European Union.
KalVista Pharmaceuticals shares fell 2.2% to close at $15.61 on Tuesday.
Benzinga readers can access the most recent expert rankings on the Expert Stock Scores page. Readers can arrange by stock ticker, business name, expert company, ranking modification or other variables.
Let’s take a look at how Benzinga’s most-accurate experts have actually ranked the business in the current duration.
- HC Wainright & & Co. expert Andrew Fein restated a Buy ranking with a rate target of $27 on July 11, 2025. This expert has a precision rate of 68%.
- JMP Securities expert Jonathan Wolleben preserved a Market Outperform ranking and increased the rate target from $19 to $27 on July 8, 2025. This expert has a precision rate of 73%.
- Leerink Partners expert Joseph Schwartz preserved an Outperform ranking and enhanced the rate target from $18 to $20 on July 7, 2025. This expert has a precision rate of 65%.
- Needham expert Serge Belanger restated a Buy ranking with a rate target of $28 on April 8, 2025. This expert has a precision rate of 75%.
- People Capital Markets expert Jonathan Wolleben restated a Market Outperform ranking with a rate target of $19 on March 26, 2025. This expert has a precision rate of 73%.
Thinking about purchasing KALV stock? Here’s what experts believe:
Read This Next:
Image by means of Shutterstock
Market News and Data gave you by Benzinga APIs